A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)

NCT07282847 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Pompe Disease (Late-onset)
Pompe Disease Late-Onset
LOPD

Interventions

GENETIC: AB-1009 (GAA Gene)

Sponsor

AskBio Inc

Collaborators

[object Object]